Validity and Feasibility of the Pregnancy Monitoring Belt - a Clinical Pilot Study
Launched by ANNA AXELIN · Nov 8, 2024
Trial Information
Current as of August 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is designed to test a new device called the pregnancy monitoring belt, which aims to help keep track of important information during pregnancy. The study will check if the belt can accurately measure things like the mother’s heart rate, fetal heart rate, and contractions, as well as how well the mother is breathing and her blood pressure. It will also look at whether pregnant women and healthcare professionals find the belt easy to use and acceptable. Additionally, the study will explore if using this device can help parents feel more connected with their unborn baby.
To participate in this trial, pregnant women need to be at least 18 years old, have a single pregnancy, and be at least 29 weeks along. The trial will take place in a hospital setting where participants will wear the monitoring belt for about two hours while their data is collected. Healthcare professionals who work with pregnant women can also participate. This study is not yet recruiting participants, but it aims to gather important information that could improve prenatal care in the future.
Gender
FEMALE
Eligibility criteria
- Inclusion criteria for pregnant women:
- • duration pf pregnancy at least 29+0 weeks
- • single pregnancy
- • age at least 18 years
- • ability to participate in Finnish No exclusion criteria
- Inclusion criteria for healthcare professionals:
- • being a healthcare professional working with pregnant women
- • being able to participate in Finnish No exclusion criteria
About Anna Axelin
Anna Axelin is a distinguished clinical trial sponsor dedicated to advancing medical research through innovative and rigorous clinical studies. With a strong emphasis on patient-centered approaches, the organization aims to enhance therapeutic outcomes across various health conditions. Anna Axelin is committed to adhering to the highest ethical standards and regulatory guidelines, ensuring the integrity of trial data while prioritizing participant safety and well-being. Through collaboration with leading researchers and healthcare professionals, Anna Axelin strives to contribute valuable insights that drive the development of effective treatments and improve patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported